Fusion Antibodies (FAB) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
09 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
09 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
09 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
09 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
09 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
05 Dec 2022 07:00 AM
RNS
Half-year Report
24 Nov 2022 07:00 AM
RNS
Notice of Results
31 Oct 2022 01:47 PM
RNS
Director/PDMR Shareholding
03 Oct 2022 07:00 AM
RNS
Block admission six monthly return
23 Sep 2022 11:44 AM
RNS
Result of AGM
20 Sep 2022 01:36 PM
RNS
Director/PDMR Shareholding
15 Sep 2022 03:41 PM
RNS
Grant of options
14 Sep 2022 02:05 PM
RNS
Second Price Monitoring Extn
14 Sep 2022 02:01 PM
RNS
Price Monitoring Extension
06 Sep 2022 07:00 AM
RNS
Grant of options
01 Sep 2022 07:00 AM
RNS
Notice of AGM and Director change
23 Aug 2022 07:00 AM
RNS
Final Results
09 Aug 2022 07:00 AM
RNS
Bispecific designs patent application
05 Aug 2022 04:41 PM
RNS
Second Price Monitoring Extn
05 Aug 2022 04:35 PM
RNS
Price Monitoring Extension
28 Jul 2022 07:00 AM
RNS
Appointment of Chief Executive Officer
06 May 2022 07:00 AM
RNS
Trading update
01 Apr 2022 07:00 AM
RNS
Block admission six monthly return
14 Mar 2022 07:00 AM
RNS
Update on Board changes
28 Feb 2022 07:00 AM
RNS
Director changes
22 Feb 2022 04:41 PM
RNS
Second Price Monitoring Extn
22 Feb 2022 04:35 PM
RNS
Price Monitoring Extension
21 Feb 2022 07:00 AM
RNS
Directorate Change
10 Feb 2022 12:49 PM
RNS
Stmnt re Share Price Movement
14 Jan 2022 07:00 AM
RNS
Formation of New Scientific Advisory Panel
11 Jan 2022 01:26 PM
RNS
Holding(s) in Company
31 Dec 2021 07:00 AM
RNS
Total Voting Rights
16 Dec 2021 07:00 AM
RNS
Exercise of share options and total voting rights
14 Dec 2021 07:00 AM
RNS
Exercise of share options and total voting rights
06 Dec 2021 07:00 AM
RNS
Half-year Report
02 Dec 2021 07:00 AM
RNS
Update on R&D
17 Nov 2021 10:00 AM
RNS
Notice of Results
19 Oct 2021 04:25 PM
RNS
Grant of options
07 Oct 2021 04:40 PM
RNS
Second Price Monitoring Extn
07 Oct 2021 04:35 PM
RNS
Price Monitoring Extension
07 Oct 2021 02:06 PM
RNS
Second Price Monitoring Extn
07 Oct 2021 02:00 PM
RNS
Price Monitoring Extension
07 Oct 2021 11:06 AM
RNS
Second Price Monitoring Extn
07 Oct 2021 11:00 AM
RNS
Price Monitoring Extension
07 Oct 2021 07:00 AM
RNS
New contract win
27 Sep 2021 07:00 AM
RNS
Total Voting Rights
24 Sep 2021 12:00 PM
RNS
Result of AGM
24 Sep 2021 07:00 AM
RNS
AGM Statement
01 Sep 2021 07:00 AM
RNS
Notice of AGM

Fusion Antibodies is a biotechnology company that specializes in antibody development services for the healthcare industry. The company was founded in 2001 as a spin-out from Queen's University Belfast and is headquartered in Belfast, Northern Ireland. Fusion Antibodies offers antibody discovery, engineering, supply, and cell line development. It has developed proprietary technology platforms such as CDRx® for antibody humanization, RAMP® for affinity maturation, and ADD™ for developability optimization.

FAB share price launched at 165p in 2017.

UK 100

Latest directors dealings